Xuan-Yu Wang
LightNews LightNews
banner
daxenor.bsky.social
Xuan-Yu Wang
@daxenor.bsky.social
39 followers 180 following 2 posts
Passionate about advancing cardiometabolic research through cutting-edge multi-omics, GWAS, network pharmacology, and molecular docking.
Posts Replies Media Videos
Pinned
daxenor.bsky.social
Xuan-Yu Wang @daxenor.bsky.social · Jun 4
🥳New study in Metab Target Organ Damage reveals genetic links between MASLD and cardiometabolic traits.
📍Our multi-omics research redefines the liver-heart axis, opening doors to new therapies.
😊Read, Share, Cite!👉https://www.oaepublish.com/articles/mtod.2024.129

#Cardiometabolic #CAD #MASLD #T2D
🌟 New Research Findings: "Exciting developments in the field of cardiometabolic health! Our team's latest research, published in Metabolism and Target Organ Damage (M&TOD), delves into the genetic architecture linking metabolic dysfunction-associated steatotic liver disease (MASLD) with cardiometabolic traits. Discover how our genome-wide pleiotropic and multi-omics study is reshaping our understanding of liver-heart axis interactions and opening new avenues for therapeutic innovation." 🔬🧬 📚 How to Cite: Wang XY, Lyu Q, Zhang YY, Su Y, Zhao H, Shen HH, Xie YY. Shared genetic architecture between metabolic dysfunction-associated steatotic liver disease and cardiometabolic traits comorbidities: a genome-wide pleiotropic and multi-omics study. Metab Target Organ Damage. 2025;5:23. http://dx.doi.org/10.20517/mtod.2024.129
daxenor.bsky.social
🥳New study in Metab Target Organ Damage reveals genetic links between MASLD and cardiometabolic traits.
📍Our multi-omics research redefines the liver-heart axis, opening doors to new therapies.
😊Read, Share, Cite!👉https://www.oaepublish.com/articles/mtod.2024.129

#Cardiometabolic #CAD #MASLD #T2D
🌟 New Research Findings: "Exciting developments in the field of cardiometabolic health! Our team's latest research, published in Metabolism and Target Organ Damage (M&TOD), delves into the genetic architecture linking metabolic dysfunction-associated steatotic liver disease (MASLD) with cardiometabolic traits. Discover how our genome-wide pleiotropic and multi-omics study is reshaping our understanding of liver-heart axis interactions and opening new avenues for therapeutic innovation." 🔬🧬 📚 How to Cite: Wang XY, Lyu Q, Zhang YY, Su Y, Zhao H, Shen HH, Xie YY. Shared genetic architecture between metabolic dysfunction-associated steatotic liver disease and cardiometabolic traits comorbidities: a genome-wide pleiotropic and multi-omics study. Metab Target Organ Damage. 2025;5:23. http://dx.doi.org/10.20517/mtod.2024.129
June 4, 2025 at 10:59 AM